Abstract: A surgical tool for use with a drill bit to prevent skiving at an implant insertion site on a bone includes a cannulated sleeve having a distal end defining a burr surface. The distal end may be detachable from a body of the cannulated sleeve. The tool may be used with more than one distal end, each of the distal ends defining a burr surface having a different cutting surface from the others. The tool may form a system that includes the drill bit.

Abstract: A surgical tool for use with a drill bit to prevent skiving at an implant insertion site on a bone includes a cannulated sleeve having a distal end defining a burr surface. The distal end may be detachable from a body of the cannulated sleeve. The tool may be used with more than one distal end, each of the distal ends defining a burr surface having a different cutting surface from the others. The tool may form a system that includes the drill bit.

Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.

Abstract: A surgical tool for use with a drill bit to prevent skiving at an implant insertion site on a bone includes a cannulated sleeve having a distal end defining a burr surface. The distal end may be detachable from a body of the cannulated sleeve. The tool may be used with more than one distal end, each of the distal ends defining a burr surface having a different cutting surface from the others. The tool may form a system that includes the drill bit.

Abstract: The invention relates to ex-situ biosensors that impedimetrically detect one or more target biomarkers of interest in bodily fluid sample derived from a patient. The biosensors include a multi-array of conducting material, such as platinum wires, having immobilized thereon antibody and/or aptamer that is selected to specifically and selectively bind to the one or more target biomarkers of interest. The biosensors are contacted with a portion of the bodily fluid sample, and the antibody and/or aptamer binds to the target biomarker(s) of interest in the bodily fluid sample. As a result, an electrochemical impedance signal is generated and therefore, a change in the electrochemical impedance is indicative of the presence of the target biomarker(s) of interest in the bodily fluid sample. The biosensors are point-of-care, on-demand devices that can be used in a medical environment, as well as in domestic and health emergency settings.

Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.

Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.

Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.

Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.